NASDAQ:EXEL - Exelixis Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$21.29 -0.05 (-0.23 %)
(As of 07/23/2018 03:53 AM ET)
Previous Close$21.29
Today's Range$21.12 - $21.46
52-Week Range$18.50 - $32.50
Volume2.32 million shs
Average Volume6.54 million shs
Market Capitalization$6.32 billion
P/E Ratio25.65
Dividend YieldN/A
Beta2.09
Exelixis logoExelixis, Inc., a biotechnology company, engages in the discovery, development, and commercialization of new medicines to enhance care and outcomes for people with cancer. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. It also offers COTELLIC tablets, an inhibitor of MEK in combination with vemurafenib for the treatment of patients with BRAF V600E or V600K mutation-positive advanced melanoma in the United States; and in combination with vemurafenib in other territories, including the European Union, Switzerland, Canada, Australia, and Brazil. Exelixis, Inc. has collaboration and license agreement with Ipsen Pharma SAS, Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, Daiichi Sankyo Company Limited, and Invenra, Inc. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.

Receive EXEL News and Ratings via Email

Sign-up to receive the latest news and ratings for EXEL and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Commercial physical research
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:EXEL
CUSIP30161Q10
Phone650-837-7000

Debt

Debt-to-Equity RatioN/A
Current Ratio6.67
Quick Ratio6.58

Price-To-Earnings

Trailing P/E Ratio25.65
Forward P/E Ratio25.05
P/E GrowthN/A

Sales & Book Value

Annual Sales$452.48 million
Price / Sales13.97
Cash Flow$0.5470 per share
Price / Cash38.92
Book Value$0.96 per share
Price / Book22.18

Profitability

EPS (Most Recent Fiscal Year)$0.51
Net Income$154.22 million
Net Margins43.39%
Return on Equity77.39%
Return on Assets40.62%

Miscellaneous

Employees372
Outstanding Shares296,870,000
Market Cap$6,320.28

Exelixis (NASDAQ:EXEL) Frequently Asked Questions

What is Exelixis' stock symbol?

Exelixis trades on the NASDAQ under the ticker symbol "EXEL."

How were Exelixis' earnings last quarter?

Exelixis, Inc. (NASDAQ:EXEL) issued its quarterly earnings data on Wednesday, May, 2nd. The biotechnology company reported $0.37 earnings per share for the quarter, topping the consensus estimate of $0.16 by $0.21. The biotechnology company had revenue of $212.35 million for the quarter, compared to analysts' expectations of $146.39 million. Exelixis had a net margin of 43.39% and a return on equity of 77.39%. View Exelixis' Earnings History.

What price target have analysts set for EXEL?

12 Wall Street analysts have issued 12 month target prices for Exelixis' stock. Their predictions range from $28.00 to $40.00. On average, they anticipate Exelixis' stock price to reach $33.5556 in the next twelve months. This suggests a possible upside of 57.6% from the stock's current price. View Analyst Ratings for Exelixis.

What is the consensus analysts' recommendation for Exelixis?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Exelixis in the last year. There are currently 3 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

What are Wall Street analysts saying about Exelixis stock?

Here are some recent quotes from research analysts about Exelixis stock:
  • 1. Cann analysts commented, "We had anticipated a PDUFA date for this sNDA filing in H2 2018; as a result of the January 2019 PDUFA date we are slightly adjusting sales and EPS for 2018. Based on the timing of the PDUFA date, we are slightly delaying our estimated launch for Cabometyx in HCC. As a result we are decreasing our estimated 2018 revenue estimate by 3.5%, to $649.0 million from $672.8 million. We are reducing our estimated EPS in 2018 by 9.6%, to $0.67 from our prior estimate of $0.74. Our outlook for 2019 – 2022 revenue is unchanged." (5/30/2018)
  • 2. According to Zacks Investment Research, "Exelixis’ first-quarter results were impressive wherein both earnings and sales beat estimates by a wide margin. Demand for Cabometyx grew by approximately 30% sequentially driven by increases in new patient starts and refills for patients already on therapy. We expect sales to get a further boost in 2018 as the drug is now approved for first-line RCC which will increases the eligible patient population for Caobometyx in the United States by approximately 14,000 patients and grab market share from two key drugs — Sutent and Votrient in the first-line RCC market. A potential label expansion for advanced HCC will further boost the growth prospects of the company. However, competition has further stiffened up with the recent approval of Opdivo and Yervoy for the treatment of poor and intermediate risk first-line RCC. A label expansion of Cotellic will also boost the sales. Shares have outperformed the industry in the last twelve months." (5/15/2018)

Are investors shorting Exelixis?

Exelixis saw a increase in short interest in June. As of June 29th, there was short interest totalling 14,630,180 shares, an increase of 39.2% from the June 15th total of 10,511,874 shares. Based on an average daily volume of 9,157,501 shares, the days-to-cover ratio is presently 1.6 days. Approximately 5.1% of the company's stock are short sold. View Exelixis' Current Options Chain.

Who are some of Exelixis' key competitors?

Who are Exelixis' key executives?

Exelixis' management team includes the folowing people:
  • Dr. Stelios Papadopoulos, Co-Founder & Chairman (Age 70)
  • Dr. Michael M. Morrissey, CEO, Pres & Director (Age 57)
  • Mr. Christopher J. Senner, Exec. VP & CFO (Age 50)
  • Dr. Peter Lamb, Exec. VP of Scientific Strategy & Chief Scientific Officer (Age 57)
  • Mr. Jeffrey J. Hessekiel, Exec. VP, Gen. Counsel & Sec. (Age 49)

Has Exelixis been receiving favorable news coverage?

Media headlines about EXEL stock have been trending positive recently, according to Accern Sentiment. The research group scores the sentiment of news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Exelixis earned a news sentiment score of 0.35 on Accern's scale. They also assigned news stories about the biotechnology company an impact score of 45.33 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near term.

Who are Exelixis' major shareholders?

Exelixis' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Rhenman & Partners Asset Management AB (0.32%), Chicago Capital LLC (0.20%), Bank of Montreal Can (0.13%), Retirement Systems of Alabama (0.12%), Handelsbanken Fonder AB (0.11%) and Creative Planning (0.03%). Company insiders that own Exelixis stock include Alan M Garber, Carl B Feldbaum, Charles Cohen, Christopher J Senner, George A Scangos, George Poste, Gisela Schwab, Jack L Wyszomierski, Jeffrey Hessekiel, Lance Willsey, Michael Morrissey, Patrick J Haley, Peter Lamb, Stelios Papadopoulos and Vincent T Marchesi. View Institutional Ownership Trends for Exelixis.

Which institutional investors are selling Exelixis stock?

EXEL stock was sold by a variety of institutional investors in the last quarter, including Creative Planning. Company insiders that have sold Exelixis company stock in the last year include Alan M Garber, Carl B Feldbaum, Charles Cohen, Christopher J Senner, George Poste, Gisela Schwab, Jeffrey Hessekiel, Lance Willsey, Michael Morrissey, Patrick J Haley, Stelios Papadopoulos and Vincent T Marchesi. View Insider Buying and Selling for Exelixis.

Which institutional investors are buying Exelixis stock?

EXEL stock was acquired by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, Bank of Montreal Can, Retirement Systems of Alabama, Chicago Capital LLC, Louisiana State Employees Retirement System, Oakbrook Investments LLC, Handelsbanken Fonder AB and LS Investment Advisors LLC. View Insider Buying and Selling for Exelixis.

How do I buy shares of Exelixis?

Shares of EXEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Exelixis' stock price today?

One share of EXEL stock can currently be purchased for approximately $21.29.

How big of a company is Exelixis?

Exelixis has a market capitalization of $6.32 billion and generates $452.48 million in revenue each year. The biotechnology company earns $154.22 million in net income (profit) each year or $0.51 on an earnings per share basis. Exelixis employs 372 workers across the globe.

How can I contact Exelixis?

Exelixis' mailing address is 210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-837-7000 or via email at [email protected]


MarketBeat Community Rating for Exelixis (NASDAQ EXEL)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  338 (Vote Outperform)
Underperform Votes:  279 (Vote Underperform)
Total Votes:  617
MarketBeat's community ratings are surveys of what our community members think about Exelixis and other stocks. Vote "Outperform" if you believe EXEL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EXEL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/23/2018 by MarketBeat.com Staff

Featured Article: What are CEFs?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.